Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology

With increasing numbers of bispecific antibodies (BsAbs) and multispecific products entering the clinic, recent data highlight immunogenicity as an emerging challenge in the development of such novel biologics. This review focuses on the immunogenicity risk assessment (IgRA) of BsAb-based immunother...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yanchen, Penny, Hweixian L, Kroenke, Mark A, Bautista, Bianca, Hainline, Kelly, Chea, Lynette S, Parnes, Jane, Mytych, Daniel T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024276/
https://www.ncbi.nlm.nih.gov/pubmed/35444060
http://dx.doi.org/10.1136/jitc-2021-004225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024276/
https://www.ncbi.nlm.nih.gov/pubmed/35444060
http://dx.doi.org/10.1136/jitc-2021-004225

Ejemplares similares